Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression

MRC · United Kingdom government procurement

Closed September 29, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Monocarboxylate transporter 1 (MCT1) is a transmembrane protein involved in cell metabolism and mediates transport of monocarboxylates (such as pyruvate {a metabolic substrate} and lactate {a metabolic by product}) in and out of the cell. Increased plasma membrane (PM) expression of MCT1 has been reported in several cancer types including endometrial cancer (EC) and is associated with reduced patient survival. Although nucleus is not a usual location for MCTs (based on current knowledge on their function), we and others reported nuclear MCT1 (nMCT1) expression in endometrial [2] and soft sarcoma [3] biopsies. Both studies showed that patients with nMCT1 survive longer than the patients without it. Further, a number of studies showed that metabolic proteins found in the nucleus can regulate transcription and chromatin remodelling by acting as co-factors or by providing the substrates (such as lactate, acetyl-coA) for these processes (reviewed in [4, 5]). Interestingly, we also found that when in nucleus, MCT1 interacts with other proteins that modify chromatin remodelling and regulate gene expression. Therefore, understanding nMCT1's novel role in nucleus is vital to identify and exploit novel approaches in cancer treatment to enhance life-expectancy amongst patients. This project aims to identify nMCT1s role in relation to potential chromatin remodelling and/or metabolomic changes involved in cancer progression and patient survival. For this purpose, we will first combine CRISPR-Cas9 technology with molecular cloning to engineer cancer cell lines (Ishikawa and HEC1A) with MCT1 protein targeted specifically to the nucleus (nMCT1) or plasma membrane (PM MCT1). We will then subject these cell lines to a number of in vitro methods (e.g. immunofluorescence, western blotting, electron microscopy) to characterise subcellular localisation and expression levels in engineered cell lines. Metabolic profile of the engineered cell lines with nMCT1 wand PM MCT1 will be performed...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
ClosedSeptember 29, 2026
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Understanding the mechanisms of treatment resistance in colorectal cancer using organoid models
Characterising the role of TEX12 in centrosome and cilia development
Using core genes and pathways to stratify rheumatoid arthritis and predict outcomes in Rheumatoid Arthritis
Disorders of attention, awareness and cognitive control
Motivational Brain Circuits for Behavioural Flexibility
Understanding Patient Data (UPD)
Mobile electroencephalography & computational modelling to understand the role of sleep in disease progression in amnestic mild cognitive impairment

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.